47 KB99 KB30 KB199220252002Janku, Filipštevilka:2letnik:369 stranistr. 121-129ISSN:1318-2099COBISSID:15184601URN:URN:NBN:SI:doc-2UBIBGEIenAssociation of Radiology and OncologyRadiology and oncology (Ljubljana)Analiza preživetjaAntagonists and inhibitorsbreastBreast neoplasmsDojka, novotvorbedojkeDrug therapyIzid zdravljenjaKarnofsky performance statusKarnofskyva ocena sposobnostiNeoplasm metastasisNovotvorba, metastazanovotvorbeProspective studiesProspektivne študijeProto-oncogene proteins c-erbb-2Survival analysistherapyTreatment outcometumorzdravljenjeEfficacy of weekly trastuzumab and paclitaxel in the treatment of women with HER-2/neu overexpressing metastatic breast cancer| the impact of taxane free interval on treatment outcomes|Purpose. Trastuzumab is known as an active agent in HER2/neu overexpressing metastatic breast cancer. In the prospective study we investigated efficacy, safety and toxicity of trastuzumab and paclitaxel in metastatic breast cancer progressing on previous therapy. Patients and methods. We accrued 17 patients with histologically confirmed breast cancer, Karnofsky performance status at least 60 %, median age 50 (36-66), pretreated with at least two regimens. HER-2/neu expression was tested by HercepTest (r) (DAKO) in all 17 patients. Fifteen specimens were 3+ positive and 2 specimens 2+ positive. All patients except one were pretreated with taxanes. Taxane free interval (TFI) was defined as a time from last taxane administration until the beginning of the study for every enrolled patient. TFI longer than 1 year was found in 7 patients. TFI shorter than 1 year was observed in 9 patients. Trastuzumab was given 4 mg/kg i.v. as a loading dose followed by 2 mg/kg i.v. weekly. Paclitaxel was given 80 mg/m2 i.v. weekly until disease progression or unacceptable toxicity. We assessed the response rate (RR), the time to progression (TTP), the survival (OS) and toxicity. (Abstract truncated at 2000characters)Izhodišče. Trastuzumab je poznan kot učinkovito zdravilo pri bolnicah z rakom dojke in izraženem HER2/neu onkogenom. V prospektivni študiji smo proučevali učinkovitost, varnost in toksičnost trastuzumaba in paclitaxela pri metastatskem raku dojke, ki je bil v progresu po predhodnem zdravljenju. Bolniki in metode. Vključili smo 17 bolnic z histološko potrjenim rakom dojke,s stanjem zmogljivosti po Karnofskem vsaj 60 %, srednjo starostjo 50 let(36-66), ki so bile prej zdravljene z vsaj dvema shemama kemoterapije. Izražanje HER-2/neu smo preverjali z Herceptest (DAKO) pri vseh 17 bolnicah. Petnajst vzorcev je bilo 3+ positivnih, dva vzorca pa 2+ positivna. Vse bolnice razen ene so bile prej zdravljene s taksani. Interval brez taksanov (TFI) smo definirali kot čas med zadnjo aplikacijo taksanov in pričetkom študije za vsako bolnico posebej. TFI je bil daljši od enega leta pri 7 bolnicah, TFI krajši od enega leta pa pri 9. Začetna doza Trastuzumaba je bila4 mg/kg i.v., nato pa 2 mg/kg i.v. vsak teden. Paclitaxel smo aplicirali vdozi 80 mg/mz i.v. vsak teden do napredovanja bolezni ali pa nesprejemljive toksičnosti. Ocenjevali smo stopnjo odgovora (RR), čas do napredovanja bolezni(TTP), preživetje (OS) in toksičnost. (Izvleček skrajšan pri 2000 znakih)TEXTznanstveno časopisjejournalsSlovenian National E-content AggregatorNational and University Library of SloveniaDruštvo radiologije in onkologije